CRISPR Therapeutics
610 Main Street
Cambridge
Massachusetts
02142
United States
Tel: 617-580-9212
Website: http://crisprtx.com/
Email: info@crisprtx.com
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.
266 articles about CRISPR Therapeutics
-
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
6/2/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress.
-
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
5/31/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.
-
CRISPR Therapeutics tapped Amgen veteran Phuong Khanh (P.K.) Morrow, M.D., FACP, as its new chief medical officer.
-
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
5/16/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer, effective May 23, 2022.
-
CRISPR reported that the overall response rate (ORR) was 71% with 29% of patients experiencing a complete response. The data will be presented at EHA 2022.
-
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
5/12/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress.
-
CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.
-
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
5/4/2022
CRISPR Therapeutics announced that members of its senior management team are scheduled to participate in the 2022 Bank of America Healthcare Conference on Wednesday, May 11, 2022, at 4:40 p.m. PT.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
Vertex has made a point over the past decade to make research and development a priority, investing over 70% of its expenses back into it.
-
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
4/12/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of Directors at the Company’s upcoming annual general of shareholders meeting to be held later this year.
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Apr 07, 2022
4/7/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following investor conferences in April.
-
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
3/8/2022
CRISPR Therapeutics announced that it will present an e-poster at the American Association for Cancer Research 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.
-
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
CRISPR Therapeutics announced that members of its senior management team are scheduled to participate in the following investor conferences in March.
-
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2/15/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
-
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
CRISPR Therapeutics announced that members of its senior management team are scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022, at 1:40 p.m. ET.
-
It was a relatively quiet week for clinical trial announcements. Here’s a look.
-
Scientists Reveal "Rosetta Stone" of Immune Cell Function
2/4/2022
Researchers adapt a variation of the CRISPR-Cas9 system to activate genes in human immune cells and study the consequences.